Nyxoah Secures $15M from EIB to Accelerate Genio's Launch in the US
Nyxoah announced on Wednesday the release of the second tranche of its financing from the European Investment Bank (EIB), amounting to $15 million. This non-dilutive funding comes just days after closing a $95 million equity fundraising, bringing the total capital raised in June to approximately $110 million.
Non-dilutive Financing to Speed Up Commercial Launch
The EIB funds will be primarily dedicated to accelerating the commercial launch of the Genio system in the United States, while supporting investments in research and development as well as the development of production capacity. Olivier Taelman, CEO, praises the 'continuous support' from the European Investment Bank as 'a strong testament to the confidence in our technology and the long-term potential of our mission'.
Financial Expansion in North America
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The release of this tranche follows the recent confirmation that Nyxoah had met the predefined criteria to access it. Combined with this month's completed public equity offering, this EIB funding completes an intense period of financial structuring aimed at supporting the group's expansion in North America.
Related
SectorDispositifs médicaux et optique›Dispositifs médicaux
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 14 millions d'euros
Quarterly revenue: 14 millions d'euros
Revenue growth: 484,4 %
Net income: -48,9 millions d'euros
Guidance from the release
nous sommes confiants dans le fait que l'environnement de remboursement actuel soutient l'accélération de notre croissance du chiffre d'affaires aux États-Unis
Risks mentioned
Baisse de la marge brute à 59 % au S1 2026 due à des problèmes de rendement de production au T1 et à un mix de revenus américain plus important
Augmentation des charges de vente, générales et administratives liée au déploiement commercial aux États-Unis
Perte opérationnelle en hausse à 41,1 M€ au S1 2026 contre 40,5 M€ au S1 2025
Opportunities identified
Financement de 110 millions de dollars sécurisé au T2 2026 pour financer la croissance commerciale
Taux d'approbation de 100 % sur les demandes d'autorisation préalable pour les patients commerciaux et WISeR
Code Medicare C-code 8011 dédié à Genio, clarifiant le paysage de remboursement
Outlook / guidance
Expected revenue: 38 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
